Copyright
©The Author(s) 2015.
World J Clin Oncol. Aug 10, 2015; 6(4): 64-72
Published online Aug 10, 2015. doi: 10.5306/wjco.v6.i4.64
Published online Aug 10, 2015. doi: 10.5306/wjco.v6.i4.64
Figure 4 Radiographic progression-free survival of abiraterone with prednisone vs placebo with prednisone.
Hazard ratio (HR) associated with abiraterone with prednisone vs placebo with prednisone for Radiographic-PFS were calculated using random effect model. The HR and 95%CI for each trial and the final combined results are demonstrated numerically on the left and graphically as a forest plot on the right. For individual trials: filled in square, hazard ratio; lines, 95%CI; diamond plot, overall results of the included trials. PFS: Progression-free survival.
- Citation: Shameem R, Hamid MS, Xu KY, Wu S. Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer. World J Clin Oncol 2015; 6(4): 64-72
- URL: https://www.wjgnet.com/2218-4333/full/v6/i4/64.htm
- DOI: https://dx.doi.org/10.5306/wjco.v6.i4.64